Protagenic Therapeutics Azioni (NASDAQ: PTIX)

Ultime notizie per Protagenic Therapeutics (NASDAQ:PTIX) Azioni

Protagenic Therapeutics

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics Inc

WIIM

PTIX

Protagenic Therapeutics shares are trading higher. The company announced the pricing of a $1.275 million private placement.

Protagenic Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today it has entered into a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 shares of common stock (or pre-funded warrants in lieu of shares of common stock), series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock, with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term of eighteen (18) months from the Stockholder Approval Date (as defined in the Purchase Agreement), and series B common stock purchase warrants to purchase an aggregate of 1,948,295 shares of Common Stock with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date for a term of five (5) years from the Stockholder Approval Date. The purchase price of each share of common stock and associated common stock purchase warrants will be $0.64 ($0.89 in the case of insiders).
The closing of the offering is expected to occur on or before November 4, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $1.275 million, excluding any proceeds that may be received upon exercise of the warrants and before deducting fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the sale of the securities for working capital purposes.
Brookline Capital Markets, a division of Arcadia Securities, LLC, is acting as sole placement agent for the private placement.

News

Offerings

Protagenic Therapeutics Announces Pricing Of $1.275M Private Placement For The Purchase And Sale Of An Aggregate Of 1,948,295 Shares Of Common Stock; The Purchase Price Of Each Share Of Common Stock And Associated Common Stock Purchase Warrants Will Be $0.64

<h3>Gainers</h3>
<ul>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock rose 147.9% to $0.42 during Tuesday's pre-market session. The market value of their outstanding shares is at $26.8 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock rose 56.39% to $2.08. The market value of their outstanding shares is at $6.1 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares moved upwards by 55.73% to $2.04. The market value of their outstanding shares is at $4.5 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock increased by 52.83% to $0.84. The company's market cap stands at $4.1 million. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) stock increased by 29.53% to $2.5. The market value of their outstanding shares is at $14.2 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock increased by 22.44% to $0.69. The market value of their outstanding shares is at $3.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) stock declined by 23.6% to $96.46 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.2 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock declined by 19.18% to $0.25. The market value of their outstanding shares is at $7.7 million. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) stock decreased by 16.97% to $3.67. The company's market cap stands at $13.4 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares decreased by 15.01% to $1.87. The company's market cap stands at $17.7 million. </li>
<li>American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) stock decreased by 14.41% to $8.5. The company's market cap stands at $127.4 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 13.08% to $1.13. The market value of their outstanding shares is at $6.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AMWL

BIOR

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

GLYC

HCTI

IMRN

LIXT

SHPH

TMDX

TRIB

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares increased by 147.9% to $0.42 during Tuesday's pre-market session. The company's market cap stands at $26.8 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock moved upwards by 56.39% to $2.08. The market value of their outstanding shares is at $6.1 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock rose 55.73% to $2.04. The company's market cap stands at $4.5 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock rose 52.83% to $0.84. The market value of their outstanding shares is at $4.1 million. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) shares moved upwards by 29.53% to $2.5. The company's market cap stands at $14.2 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares rose 22.44% to $0.69. The market value of their outstanding shares is at $3.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares declined by 23.6% to $96.46 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.2 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares declined by 19.18% to $0.25. The company's market cap stands at $7.7 million. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) shares decreased by 16.97% to $3.67. The company's market cap stands at $13.4 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock fell 15.01% to $1.87. The company's market cap stands at $17.7 million. </li>
<li>American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) shares fell 14.41% to $8.5. The market value of their outstanding shares is at $127.4 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 13.08% to $1.13. The company's market cap stands at $6.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

<h3>Gainers</h3>
<ul>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock rose 21.4% to $0.78 during Tuesday's after-market session. The market value of their outstanding shares is at $3.4 million. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) shares increased by 11.7% to $1.05. The market value of their outstanding shares is at $17.8 million. </li>
<li>Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) shares rose 8.49% to $2.17. The market value of their outstanding shares is at $162.7 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) shares rose 6.68% to $18.99. The company's market cap stands at $1.7 billion. </li>
<li>Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) stock rose 6.15% to $2.76. The market value of their outstanding shares is at $95.3 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock rose 5.26% to $0.44. The company's market cap stands at $7.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) shares declined by 15.7% to $2.1 during Tuesday's after-market session. The market value of their outstanding shares is at $51.8 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares declined by 11.45% to $0.48. The company's market cap stands at $6.6 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock decreased by 10.59% to $3.21. The market value of their outstanding shares is at $8.3 million. </li>
<li>Allakos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) stock declined by 6.72% to $1.25. The market value of their outstanding shares is at $111.0 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) shares declined by 6.71% to $0.58. The company's market cap stands at $14.5 million. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) stock decreased by 6.67% to $4.9. The market value of their outstanding shares is at $205.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLK

CNTX

ENSC

FTRE

GNLX

GNPX

HURA

NDRA

SNSE

TELA

TLPH

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 134.8% to $0.48 during Tuesday's pre-market session. The market value of their outstanding shares is at $6.7 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock rose 118.54% to $3.3. The market value of their outstanding shares is at $8.5 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock moved upwards by 51.51% to $0.5. The market value of their outstanding shares is at $3.7 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares rose 43.17% to $3.25. The market value of their outstanding shares is at $1.6 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares rose 24.21% to $12.79. The market value of their outstanding shares is at $13.6 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares increased by 20.55% to $0.29. The market value of their outstanding shares is at $3.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares fell 24.7% to $0.99 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.9 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock declined by 21.03% to $0.62. The market value of their outstanding shares is at $15.4 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares declined by 14.11% to $0.41. The company's market cap stands at $29.5 million. </li>
<li>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares declined by 11.32% to $312.98. The market value of their outstanding shares is at $9.7 billion. The company's, Q3 earnings came out yesterday. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) shares fell 9.23% to $5.02. The market value of their outstanding shares is at $210.8 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares decreased by 8.56% to $0.64. The market value of their outstanding shares is at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADXN

APVO

ALPS ETF Trusthen & Steers Global Realty Majors ETF

INAB

MEDP

TCBP

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock moved upwards by 134.8% to $0.48 during Tuesday's pre-market session. The company's market cap stands at $6.7 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock rose 118.54% to $3.3. The company's market cap stands at $8.5 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock rose 51.51% to $0.5. The market value of their outstanding shares is at $3.7 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares rose 43.17% to $3.25. The market value of their outstanding shares is at $1.6 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares increased by 24.21% to $12.79. The company's market cap stands at $13.6 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares moved upwards by 20.55% to $0.29. The market value of their outstanding shares is at $3.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares fell 24.7% to $0.99 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.9 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock decreased by 21.03% to $0.62. The market value of their outstanding shares is at $15.4 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares decreased by 14.11% to $0.41. The market value of their outstanding shares is at $29.5 million. </li>
<li>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares decreased by 11.32% to $312.98. The market value of their outstanding shares is at $9.7 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) stock fell 9.23% to $5.02. The company's market cap stands at $210.8 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock fell 8.56% to $0.64. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

<h3>Gainers</h3>
<ul>
<li>iRhythm Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) stock rose 16.6% to $72.43 during Monday's after-market session. The company's market cap stands at $2.2 billion. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares increased by 13.63% to $0.38. The company's market cap stands at $2.8 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares moved upwards by 5.87% to $1.26. The market value of their outstanding shares is at $89.8 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock rose 5.16% to $1.39. The company's market cap stands at $2.7 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares rose 5.12% to $0.2. The market value of their outstanding shares is at $21.7 million. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares increased by 4.99% to $0.84. The market value of their outstanding shares is at $119.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) shares declined by 20.5% to $0.62 during Monday's after-market session. The market value of their outstanding shares is at $15.5 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares fell 13.27% to $0.41. The company's market cap stands at $29.8 million. </li>
<li>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) stock decreased by 12.17% to $310.0. The company's market cap stands at $9.6 billion. As per the press release, Q3 earnings came out today. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares declined by 9.28% to $1.37. The market value of their outstanding shares is at $3.5 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares declined by 8.56% to $0.64. The company's market cap stands at $2.8 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock declined by 7.48% to $0.99. The company's market cap stands at $3.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTOR

CYCC

IRTC

WINT

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock rose 89.7% to $0.72 during Friday's after-market session. The market value of their outstanding shares is at $122.8 million. </li>
<li>Allakos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) stock rose 5.75% to $0.69. The market value of their outstanding shares is at $61.2 million. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) stock rose 5.4% to $0.39. The company's market cap stands at $36.7 million. </li>
<li>Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares increased by 5.02% to $0.26. The company's market cap stands at $14.4 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares rose 4.99% to $0.54. The company's market cap stands at $2.3 million. </li>
<li>Immunome (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) shares moved upwards by 4.98% to $12.84. The market value of their outstanding shares is at $771.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock fell 8.4% to $0.95 during Friday's after-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock fell 7.79% to $3.79. The market value of their outstanding shares is at $5.0 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares declined by 7.56% to $0.72. The market value of their outstanding shares is at $7.6 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares fell 7.14% to $0.91. The company's market cap stands at $9.2 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) shares fell 6.88% to $0.45. The company's market cap stands at $36.2 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock fell 6.36% to $0.17. The company's market cap stands at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

AKAN

BLRX

CARA

DWTX

IMNM

NIVF

TVGN

UNCY

12 Health Care Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares increased by 51.8% to $0.91 during Friday's regular session. The market value of their outstanding shares is at $9.2 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock rose 22.41% to $0.3. The market value of their outstanding shares is at $7.0 million. </li>
<li>Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) stock rose 21.29% to $1.88. The company's market cap stands at $512.3 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) stock rose 18.15% to $0.47. The company's market cap stands at $1.5 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock moved upwards by 17.99% to $1.64. The market value of their outstanding shares is at $3.0 million. </li>
<li>Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) stock increased by 16.08% to $3.68. The company's market cap stands at $97.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) shares fell 13.4% to $11.47 during Friday's regular session. The market value of their outstanding shares is at $773.3 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares declined by 13.37% to $0.51. The company's market cap stands at $2.2 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock decreased by 10.15% to $6.2. The market value of their outstanding shares is at $80.6 million. </li>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares decreased by 9.95% to $3.53. The company's market cap stands at $3.2 million. </li>
<li>Genenta Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTA#NASDAQ">GNTA</a>) shares declined by 9.69% to $6.25. The company's market cap stands at $113.8 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) shares declined by 9.37% to $1.78. The market value of their outstanding shares is at $87.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CATX

CBUS

ENTO

GNTA

HSCS

MNOV

NUWE

PACB

12 Health Care Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares increased by 48.6% to $0.78 during Tuesday's pre-market session. The company's market cap stands at $7.6 million. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) stock rose 27.9% to $3.3. The company's market cap stands at $44.1 million. </li>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) stock rose 13.99% to $0.81. The company's market cap stands at $4.6 million. </li>
<li>Sagimet Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMT#NASDAQ">SGMT</a>) shares moved upwards by 11.91% to $3.1. The company's market cap stands at $99.8 million. </li>
<li>Singular Genomics Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMIC#NASDAQ">OMIC</a>) shares increased by 9.95% to $17.23. The company's market cap stands at $43.0 million. </li>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) stock moved upwards by 9.94% to $5.53. The company's market cap stands at $59.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) stock fell 58.5% to $1.45 during Tuesday's pre-market session. The market value of their outstanding shares is at $69.2 million. </li>
<li>IGM Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>) shares declined by 23.89% to $12.59. The market value of their outstanding shares is at $746.8 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock decreased by 23.2% to $0.5. The market value of their outstanding shares is at $5.1 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock fell 19.36% to $0.56. The market value of their outstanding shares is at $2.7 million. </li>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) stock fell 17.23% to $0.48. The company's market cap stands at $56.6 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock fell 14.33% to $0.54. The market value of their outstanding shares is at $2.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADGM

APDN

CHRO

ELTX

GRTS

IGMS

OMIC

SGMT

SLXN

STTK

VRPX

<h3>Gainers</h3>
<ul>
<li>Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) stock moved upwards by 24.3% to $4.3 during Monday's pre-market session. The market value of their outstanding shares is at $516.1 million. </li>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) stock increased by 16.2% to $6.67. The company's market cap stands at $20.1 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) shares increased by 14.28% to $2.8. The market value of their outstanding shares is at $3.2 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares increased by 13.81% to $10.3. The market value of their outstanding shares is at $11.0 million. As per the news, the Q2 earnings report came out today. </li>
<li>BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) stock increased by 13.01% to $9.12. The company's market cap stands at $152.1 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares rose 9.82% to $35.0. The market value of their outstanding shares is at $1.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares fell 20.8% to $0.23 during Monday's pre-market session. The company's market cap stands at $1.9 million. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares declined by 11.66% to $4.55. The company's market cap stands at $284.6 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares decreased by 11.28% to $0.55. The company's market cap stands at $2.4 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) shares decreased by 10.93% to $1.06. The market value of their outstanding shares is at $38.5 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock declined by 10.13% to $0.57. The company's market cap stands at $7.6 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares decreased by 7.5% to $0.66. The market value of their outstanding shares is at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANAB

BNOX

BWAY

CRVS

ESLA

PRME

THAR

TRAW

VERO

12 Health Care Stocks Moving In Monday's Pre-Market Session

Shares of Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) rose sharply in today's pre-market trading after the company entered into debt-for-equity exchange agreements and <a href="https://www.benzinga.com/quote/XCUR/news">regained Nasdaq compliance.</a>
Exicure shares jumped 49.3% to $2.39 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>NuCana plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) gained 94.4% to $4.94 in pre-market trading. NuCana presented final data from Phase 2 Nutide:701 study at ESMO Congress on NUC-7738 in combination with pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy.</li>
<li>Dermata Therapeutics, Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) rose 73.4% to $2.74 in today's pre-market trading after gaining around 7% on Tuesday.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) gained 53.1% to $2.68 in the pre-market trading session. Agape ATP shares jumped over 20% on Friday after the company announced it entered into a strategic collaboration with Xiamen Photons Solar Technology that focusing on developing solar photovoltaic mounting systems in ASEAN countries.</li>
<li>Tenon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) gained 22.1% to $9.22 in pre-market trading after jumping around 72% on Friday. The company announced the pricing of a $4.5 million public offering of 1.22 million shares and warrants.</li>
<li>iTeos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) rose 20.1% to $20.05 in pre-market trading. iTeos Therapeutics announced follow-up interim data from GALAXIES Lung-201 Phase 2 platform study sponsored by GSK, for Belrestotug+Dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer.</li>
<li>IO Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) rose 18.2% to $0.8874 in pre-market trading. IO Biotech announced data from Phase 2 Basket trial of IO102-IO103, therapeutic cancer vaccine candidate, in combination with Merck&#8217;s Keytruda at the 2024 ESMO Congress.</li>
<li>Yunji Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YJ#NASDAQ">YJ</a>) gained 14.3% to $2.48 in pre-market trading after gaining 12% on Friday.</li>
<li>Adagene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAG#NASDAQ">ADAG</a>) shares rose 13.7% to $ 3.97 in pre-market trading. Adagene announced new ADG126 clinical data from ongoing Phase 1b/2 trial of SAFEbody Plus Keytruda Combo Presented at the ESMO Congress.</li>
<li>Entero Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) gained 9% to $0.38 in pre-market trading after gaining around 6% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Rafael Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) fell 40.1% to $1.00 in pre-market trading after gaining 9% on Friday.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) shares dipped 21.8% to $4.65 in pre-market trading after surging 143% on Friday.</li>
<li>Presidio Property Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQFT#NASDAQ">SQFT</a>) fell 20.4% to $0.55 in pre-market trading.</li>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares fell 16.7% to $0.13 in pre-market trading. Psyence Biomedical announced the receipt of staff delisting determination from Nasdaq.</li>
<li>Edgio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGIO#NASDAQ">EGIO</a>) shares declined 14.7% to $1.33 in pre-market trading after dipping 27% on Friday.</li>
<li>Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 11.6% to $0.48 in pre-market trading after dipping around 67% on Friday.</li>
<li>Protagenic Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares fell 11.4% to $0.7001 in pre-market trading after declining 9% on Friday.</li>
<li>Purple Biotech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) shares declined 11.2% to $0.3438 in pre-market trading after gaining 7% on Friday.</li>
<li>LeddarTech Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) fell 9.4% to $0.4001 in today's pre-market trading.</li>
<li>Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) declined 8.2% to $24.60 in pre-market trading after gaining around 5% on Friday.</li>
</ul>
<a href="https://www.benzinga.com/markets/24/09/40860420/jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics">Now Read This: </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40860420/jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics">Jim Cramer: &#8216;Hold On&#8217; To Builders FirstSource, &#8216;Here&#8217;s The Problem&#8217; With Viking Therapeutics</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

ADAG

ATPC

DRMA

EGIO

IOBT

ITOS

LDTC

NCNA

PPBT

SQFT

TNON

XCUR

Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket

Shares of Champions Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) rose sharply in today's pre-market trading reported better-than-expected financial results for the <a href="https://www.benzinga.com/quote/CSBR/earnings">first quarter on Wednesday.</a>
The company reported quarterly earnings of 11 cents per share which beat the analyst consensus estimate of a loss of $0.3 per share.
Champions Oncology shares jumped 13.5% to $4.55 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Smart for Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMFL#NASDAQ">SMFL</a>) gained 89.4% to $1.61 in pre-market trading. HRT Financial LP acquired a new stake in Smart for Life.</li>
<li>Protagenic Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) rose 58% to $1.58 in today's pre-market trading.</li>
<li>N2OFF, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NITO#NASDAQ">NITO</a>) gained 42.4% to $0.4273 in the pre-market trading session after the company announced a potential 10% increase in capacity for its Solar PV Joint Venture Project with Solterra Renewable Energy.</li>
<li>NETGEAR, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTGR#NASDAQ">NTGR</a>) shares gained 27.8% to $20.37 in pre-market trading after the company disclosed a settlement agreement with TP-Link Systems and raised its third-quarter revenue guidance.</li>
<li>Perfect Moment Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMNT#NASDAQ">PMNT</a>) gained 18.6% to $1.15 in pre-market trading after declining around 8% on Wednesday.</li>
<li>Signing Day Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGN#NYSE">SGN</a>) gained 14.4% to $0.1419 in pre-market trading.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) rose 13.8% to $0.1983 in pre-market trading after dipping 14% on Wednesday. Pineapple Energy recently entered into exchange agreements to swap Series A preferred stock and warrants for Series C preferred stock, convertible at $0.45 per share.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) rose 8.7% to $3.94 in pre-market trading. ImmunityBio recently presented long-term overall survival data in non-small cell lung cancer patients and announced registrational intent Phase 3 trials with ANKTIVA and checkpoint immunotherapy at the World Conference on Lung Cancer.</li>
<li>Applied Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) gained 5% to $5.47 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Ryde Group Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#NYSE">RYDE</a>) fell 61.7% to $5.02 in pre-market trading after dipping more than 35% on Wednesday.</li>
<li>Syra Health Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) fell 48.4% to $0.4128 in pre-market trading. Syra Health priced its $2.1 million public offering with shares and warrants priced at $0.64 each.</li>
<li>Telesis Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares dipped 40% to $1.02 in pre-market trading. Telesis Bio shares dipped 55% on Wednesday after the company announced that it has notified the Nasdaq Stock Market of its decision to delist.</li>
<li>CN Energy Group. Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>) shares fell 25.9% to $1.03 in pre-market trading. CN Energy Group received Nasdaq notice that it is currently not in compliance with certain requirements under relevant listing rules.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) shares declined 17.7% to $2.59 in pre-market trading after the company announced a $5.35 million private placement.</li>
<li>FTC Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) shares fell 16.4% to $0.3841 in pre-market trading. FTC Solar shares jumped 104% on Wednesday after the company announced that it has been selected by Strata Clean Energy to supply approximately 500 megawatts of its Voyager 2P solar tracker technology for multiple project sites in the U.S. and will be the preferred 2P solar tracker supplier over a three-year initial term.</li>
<li>iSpecimen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) fell 14.5% to $0.21 in today's pre-market trading after the company announced a 1-for-20 reverse stock split.</li>
<li>Oxford Industries, Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) shares declined 10.3% to $75.02 in pre-market trading after the company reported weaker-than-expected earnings and sales results for the second quarter. The company said it sees FY24 net sales of $1.51 billion to $1.54 billion and adjusted earnings of $7 to $7.30 per share.</li>
<li>Cadrenal Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) shares fell 8.6% to $7.73 in pre-market trading after jumping around 18% on Wednesday.</li>
<li>BeiGene, Ltd.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGNE#NASDAQ">BGNE</a>) declined 6.8% to $196.80 in pre-market trading after gaining around 7% on Wednesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40813043/jim-cramer-not-the-time-to-own-oil-when-asked-about-exxon-mobil-says-ibm-is-performing-well">Jim Cramer: &#8216;Not The Time To Own Oil,&#8217; When Asked About Exxon Mobil; Says IBM Is &#8216;Performing Well&#8217;</a></li>
</ul>

APLT

BGNE

CNEY

CSBR

CVKD

FTCI

IBRX

ISPC

NITO

NTGR

PEGY

PMNT

RYDE

SMFL

SYRA

TBIO

Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares moved upwards by 118.4% to $1.07 during Thursday's regular session. The market value of their outstanding shares is at $25.5 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) stock rose 46.79% to $1.38. The company's market cap stands at $203.5 million. </li>
<li>Altamira Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTO#NASDAQ">CYTO</a>) shares increased by 29.37% to $1.85. The company's market cap stands at $4.1 million. </li>
<li>Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) stock rose 23.44% to $0.84. The company's market cap stands at $21.9 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) stock increased by 23.04% to $0.62. The market value of their outstanding shares is at $73.8 million. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) stock moved upwards by 22.39% to $0.71. The market value of their outstanding shares is at $25.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares fell 17.8% to $1.89 during Thursday's regular session. The company's market cap stands at $5.2 million. </li>
<li>Cue Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) shares fell 16.92% to $0.09. The market value of their outstanding shares is at $14.1 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares declined by 16.08% to $1.51. The company's market cap stands at $6.6 million. </li>
<li>Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) shares decreased by 15.51% to $50.05. The market value of their outstanding shares is at $5.2 billion. </li>
<li>SAB Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABS#NASDAQ">SABS</a>) shares fell 15.5% to $2.4. The market value of their outstanding shares is at $22.1 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>DermTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMTK#NASDAQ">DMTK</a>) stock declined by 14.05% to $0.36. The company's market cap stands at $12.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CYTK

CYTO

DMTK

HLTH

ONMD

PIII

RENB

SABS

SILO

12 Health Care Stocks Moving In Thursday's Intraday Session

General

Protagenic Therapeutics shares are trading lower. The company reported safety data from the single dose portion of its Phase 1 trial involving PT00114.

No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to Commence

Biotech

Protagenic Therapeutics' Reports Safety Data From Single Dose Portion Of Phase 1 Trial Involving PT00114

Protagenic Therapeutics Completes Enrollment In Single Dose Portion Of Phase 1 Of PT00114 Stress Disorder Trial

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares rose 75.3% to $1.49 during Friday's pre-market session. The company's market cap stands at $245.2 million. </li>
<li>Cryo-Cell International (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CCEL#AMEX">CCEL</a>) shares increased by 27.94% to $9.98. The market value of their outstanding shares is at $80.8 million. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) shares moved upwards by 18.33% to $0.71. The market value of their outstanding shares is at $17.4 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares rose 16.79% to $0.04. The company's market cap stands at $3.9 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) stock increased by 15.82% to $4.99. The market value of their outstanding shares is at $11.1 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock increased by 11.47% to $2.36. The company's market cap stands at $4.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares fell 15.6% to $2.05 during Friday's pre-market session. The market value of their outstanding shares is at $5.8 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares decreased by 15.58% to $2.33. The market value of their outstanding shares is at $2.8 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares declined by 13.85% to $0.25. The market value of their outstanding shares is at $1.6 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock fell 12.79% to $0.34. The company's market cap stands at $2.4 million. </li>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) shares decreased by 12.13% to $0.79. The company's market cap stands at $16.8 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares decreased by 12.03% to $1.38. The company's market cap stands at $6.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CCEL

FRES

MBRX

PCSA

VINC

WORX

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) shares moved upwards by 66.7% to $0.48 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock moved upwards by 43.18% to $2.32. The market value of their outstanding shares is at $6.6 million. </li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) shares moved upwards by 29.87% to $1.0. The market value of their outstanding shares is at $109.5 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares increased by 22.87% to $0.72. The company's market cap stands at $33.9 million. </li>
<li>Predictive Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) stock increased by 21.64% to $1.63. The company's market cap stands at $6.6 million. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) shares moved upwards by 18.93% to $4.14. The market value of their outstanding shares is at $4.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock declined by 33.1% to $1.54 during Thursday's regular session. The market value of their outstanding shares is at $2.0 million. </li>
<li>Organogenesis Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) stock decreased by 22.32% to $2.31. The market value of their outstanding shares is at $305.4 million. </li>
<li>Xylo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XYLO#NASDAQ">XYLO</a>) shares decreased by 16.35% to $1.74. The market value of their outstanding shares is at $3.2 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock declined by 14.31% to $1.4. The market value of their outstanding shares is at $6.2 million. </li>
<li>American Oncology Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) shares fell 14.14% to $3.95. The company's market cap stands at $41.8 million. </li>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) shares decreased by 13.68% to $1.01. The market value of their outstanding shares is at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AONC

BACK

EYEN

INVO

ORGO

POAI

XYLO

Protagenic Therapeutics GAAP EPS of -$1.15

Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Protagenic Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptix-stock-quote/">PTIX</a>) just reported results for the fourth quarter of 2023.<ul><li>Protagenic Therapeutics reported earnings per share of -38 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/ptix-stock-earnings-protagenic-therapeutics-for-q4-of-2023/">PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023

KOPN, BTCM and CETX among mid-day movers

Jaguar Health, Altamira Therapeutics,Erasca among healthcare movers

Jaguar Health, Altamira Therapeutics, Erasca among healthcare movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Protagenic Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptix-stock-quote/">PTIX</a>) just reported results for the first quarter of 2024.<ul><li>Protagenic Therapeutics reported earnings per share of -39 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/ptix-stock-earnings-protagenic-therapeutics-for-q1-of-2024/">PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Protagenic Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptix-stock-quote/">PTIX</a>) just reported results for the second quarter of 2024.<ul><li>Protagenic Therapeutics reported earnings per share of -36 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ptix-stock-earnings-protagenic-therapeutics-for-q2-of-2024/">PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q2 2024

Protagenic Therapeutics (PTIX) has entered into a purchase agreement for the purchase and sale of an aggregate of 1,948,295 shares of common stock,...

Protagenic Therapeutics to sell 1.95M shares at 64c in private placement

An update from Protagenic Therapeutics ( ($PTIX) ) is now available. Protagenic Therapeutics, Inc. recently closed a private placement deal raising...

Protagenic Therapeutics Raises $1.275M for Growth Initiatives

ABEO

BEAT

BTCM

CETX

CHCI

CZOO

ERAS

JAGX

KOPN

MLEC

OPRT

PALI

PROP

PTIXW

SHIM

TRSG

YYGH

Press Releases

Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders

Comments

Protagenic Therapeutics

Notizie

Ultime notizie per Protagenic Therapeutics (NASDAQ:PTIX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO